We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
50 result(s) found, displaying 1 to 10
-
Nov-2024Prescription medicine evaluationActive ingredient: cabozantinib (S)-malate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RELFYDESS relabotulinumtoxinA 100 units/mL solution for injection vial.
-
Australian Public Assessment Report (AusPAR)Sohonos (palovarotene) has been approved to treat heterotopic ossification in individuals with fibrodysplasia ossificans progressiva.
-
Prescription medicine decision summaryRelfydess (relabotulinumtoxinA, purified Botulinum toxin type A) has been approved for the temporary improvement in the appearance of glabellar lines ("frown lines") and lateral canthal lines ("crows feet").
-
Cancellation by sponsorRequested by Ipsen Pty Ltd
-
Cancellation by sponsorRequested by Ipsen Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOHONOS palovarotene 5 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOHONOS palovarotene 2.5 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOHONOS palovarotene 1.5 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOHONOS palovarotene 1 mg capsule blister pack.